CTLA4 and colorectal carcinoma: We analyzed the IPS scores of CYT-high and low CRC patients, and found that irrespective of their MMR/MSI status, CYT-high colon patients could benefit more from anti-PD1 treatment alone or in combination with anti-CTLA-4, in contrast to CYT-low patients.